0001213900-24-010557.txt : 20240206 0001213900-24-010557.hdr.sgml : 20240206 20240206161516 ACCESSION NUMBER: 0001213900-24-010557 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240206 DATE AS OF CHANGE: 20240206 GROUP MEMBERS: AISLING CAPITAL PARTNERS IV LLC GROUP MEMBERS: AISLING CAPITAL PARTNERS IV, LP GROUP MEMBERS: ANDREW N. SCHIFF GROUP MEMBERS: STEVE ELMS SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Elevation Oncology, Inc. CENTRAL INDEX KEY: 0001783032 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 841771427 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-92657 FILM NUMBER: 24600445 BUSINESS ADDRESS: STREET 1: 101 FEDERAL STREET STREET 2: SUITE 1900 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 7163711125 MAIL ADDRESS: STREET 1: 101 FEDERAL STREET STREET 2: SUITE 1900 CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: 14ner Oncology, Inc. DATE OF NAME CHANGE: 20190719 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Aisling Capital IV, LP CENTRAL INDEX KEY: 0001652910 ORGANIZATION NAME: IRS NUMBER: 474953768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 888 SEVENTH AVENUE, 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10106 BUSINESS PHONE: 212-651-6380 MAIL ADDRESS: STREET 1: 888 SEVENTH AVENUE, 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10106 SC 13G/A 1 ea192927-13ga2aisling4_eleva.htm AMENDMENT NO. 2 TO SCHEDULE 13G

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

 

SCHEDULE 13G/A

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

(Amendment No. 2)*

 

 

 

Elevation Oncology, Inc.
(Name of Issuer)

 

Common Stock, par value $0.0001 per share
(Title of Class of Securities)

 

28623U101
(CUSIP Number)

 

December 31, 2023
(Date of Event Which Requires Filing of this Statement)

 

 

 

Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:

 

☐ Rule 13d-1(b)

 

☐ Rule 13d-1(c)

 

☒ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

1.

Names of Reporting Persons

 

Aisling Capital IV, LP

2.

Check The Appropriate Box if a Member of a Group (See Instructions)

 

(a) ☐           (b) ☐

3. SEC Use Only
4.

Citizenship or Place of Organization

 

Delaware

Number of Shares
Beneficially Owned
By Each Reporting
Person With
5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

2,878,296
7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

2,878,296

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

2,878,296 (1)

10.  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)          ☐
11. 

Percent of Class Represented by Amount in Row (9)

 

6.8% (2)

12. 

Type of Reporting Person (See Instructions)

 

PN

 

(1)Represents (i) 2,834,910 shares of common stock (“Common Stock”) and (ii) 43,386 shares of Common Stock issuable in respect of 43,386 stock options (“Stock Options”) beneficially owned by the Reporting Person.

 

(2)Calculated based on 42,414,741 shares of Common Stock outstanding as of October 27, 2022 as reported on the Issuer’s Form 10-Q, filed on November 2, 2023, as increased by 43,386 shares of Common Stock issuable upon exercise of 43,386 Stock Options.

 

2

 

 

1.

Names of Reporting Persons

 

Aisling Capital Partners IV LLC

2.

Check The Appropriate Box if a Member of a Group (See Instructions)

 

(a) ☐           (b) ☐

3. SEC Use Only
4.

Citizenship or Place of Organization

 

Delaware

Number of Shares
Beneficially Owned
By Each Reporting
Person With
5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

2,878,296

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

2,878,296

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

2,878,296 (1)

10.  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)          ☐
11. 

Percent of Class Represented by Amount in Row (9)

 

6.8% (2)

12. 

Type of Reporting Person (See Instructions)

 

OO

 

(1)Represents (i) 2,834,910 shares of Common Stock and (ii) 43,386 shares of Common Stock issuable in respect of 43,386 Stock Options beneficially owned by the Reporting Person.

 

(2)Calculated based on 42,414,741 shares of Common Stock outstanding as of October 27, 2022 as reported on the Issuer’s Form 10-Q, filed on November 2, 2023, as increased by 43,386 shares of Common Stock issuable upon exercise of 43,386 Stock Options.

 

3

 

 

1.

Names of Reporting Persons

 

Aisling Capital Partners IV, LP

2.

Check The Appropriate Box if a Member of a Group (See Instructions)

 

(a) ☐           (b) ☐

3. SEC Use Only
4.

Citizenship or Place of Organization

 

Delaware

Number of Shares
Beneficially Owned
By Each Reporting
Person With
5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

2,878,296

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

2,878,296

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

2,878,296(1)
10.  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)          ☐
11. 

Percent of Class Represented by Amount in Row (9)

 

6.8% (2)

12. 

Type of Reporting Person (See Instructions)

 

PN

 

(1)Represents (i) 2,834,910 shares of Common Stock and (ii) 43,386 shares of Common Stock issuable in respect of 43,386 Stock Options beneficially owned by the Reporting Person.

 

(2)Calculated based on 42,414,741 shares of Common Stock outstanding as of October 27, 2022 as reported on the Issuer’s Form 10-Q, filed on November 2, 2023, as increased by 43,386 shares of Common Stock issuable upon exercise of 43,386 Stock Options.

 

4

 

 

1.

Names of Reporting Persons

 

Steve Elms

2.

Check The Appropriate Box if a Member of a Group (See Instructions)

 

(a) ☐           (b) ☐

3. SEC Use Only
4.

Citizenship or Place of Organization

 

USA

Number of Shares
Beneficially Owned
By Each Reporting
Person With
5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

2,878,296

7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

2,878,296

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

2,878,296(1)
10.  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)          ☐
11. 

Percent of Class Represented by Amount in Row (9)

 

6.8% (2)

12. 

Type of Reporting Person (See Instructions)

 

IN

 

(1)Represents (i) 2,834,910 shares of Common Stock and (ii) 43,386 shares of Common Stock issuable in respect of 43,386 Stock Options beneficially owned by the Reporting Person.

 

(2)Calculated based on 42,414,741 shares of Common Stock outstanding as of October 27, 2022 as reported on the Issuer’s Form 10-Q, filed on November 2, 2023, as increased by 43,386 shares of Common Stock issuable upon exercise of 43,386 Stock Options.

 

5

 

 

1.

Names of Reporting Persons

 

Andrew N. Schiff

2.

Check The Appropriate Box if a Member of a Group (See Instructions)

 

(a) ☐           (b) ☐

3. SEC Use Only
4.

Citizenship or Place of Organization

 

USA

Number of Shares
Beneficially Owned
By Each Reporting
Person With
5.

Sole Voting Power

 

0

6.

Shared Voting Power

 

2,878,296
7.

Sole Dispositive Power

 

0

8.

Shared Dispositive Power

 

2,878,296

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

2,878,296 (1)

10.  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)          ☐
11. 

Percent of Class Represented by Amount in Row (9)

 

6.8% (2)

12. 

Type of Reporting Person (See Instructions)

 

IN

 

(1)Represents (i) 2,834,910 shares of Common Stock and (ii) 43,386 shares of Common Stock issuable in respect of 43,386 Stock Options beneficially owned by the Reporting Person.

 

(2)Calculated based on 42,414,741 shares of Common Stock outstanding as of October 27, 2022 as reported on the Issuer’s Form 10-Q, filed on November 2, 2023, as increased by 43,386 shares of Common Stock issuable upon exercise of 43,386 Stock Options.

 

6

 

 

Item 1(a).

Name of Issuer:
   
  Elevation Oncology, Inc. (the “Issuer”)
   
Item 1(b). Address of Issuer’s Principal Executive Offices:
   
 

888 Seventh Ave., 12th Floor

New York, NY 10106

   
Item 2(a). Names of Persons Filing:
   
 

This statement is filed by the entities and persons listed below, each of whom is referred to herein as a “Reporting Person” and together as the “Reporting Persons”:

 

1. Aisling Capital IV, LP (“Aisling Fund IV”)


2. Aisling Capital Partners IV, LP (“Aisling GP”)


3. Aisling Capital Partners IV LLC (“Aisling LLC”)


4. Steve Elms


5. Andrew N. Schiff

   
Item 2(b). Address of the Principal Business Office or, if None, Residence:
   
 

C/O Aisling Capital Management LP

888 Seventh Ave., 12th Floor

New York, NY 10106

   
Item 2(c). Citizenship:
   
  See responses to Item 4 on each cover page.
   
Item 2(d). Title of Class of Securities:
   
  Common Stock, par value $0.0001 per share
   
Item 2(e). CUSIP Number:
   
  28623U101
   
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a(n):
   
  Not Applicable.

 

7

 

 

Item 4.

Ownership.

 

(a)   Amount beneficially owned:

See response to Item 9 on each cover page.

 

 

(b)   Percent of Class:

See response to Item 11 on each cover page.

 

 

(c)   Number of shares as to which the Reporting Person has:

 

 

(i)   Sole power to vote or to direct the vote:

See responses to Item 5 on each cover page.

 

 

(ii)  Shared power to vote or to direct the vote:

See responses to Item 6 on each cover page.

 

 

(iii) Sole power to dispose or to direct the disposition of:

See responses to Item 7 on each cover page.

 

 

(iv)  Shared power to dispose or to direct the disposition of:

See responses to Item 8 on each cover page.

 

 

The shares of Common Stock are directly held by Aisling Capital IV, LP (“Aisling Fund IV”) and the Stock Options are directly held by Steve Elms for the benefit of Aisling. Aisling Capital Partners IV, LP (“Aisling GP”), is the general partner of Aisling Fund IV, and Aisling Capital Partners IV LLC (“Aisling LLC”), is the general partner of Aisling GP. The managers of Aisling LLC are Dr. Andrew Schiff and Steve Elms, who share voting power and dispositive powers over securities held by Aisling, and as a result, may each be deemed to have beneficial ownership over such securities. This Statement shall not be construed as an admission that any of the Reporting Persons are, for purposes of Section 13(d) and 13(g), beneficial owners of the reported securities.

 

Item 5. Ownership of Five Percent or Less of a Class.
   
  Not Applicable.
   
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
   
  Not Applicable.
   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
   
  Not Applicable.
   
Item 8. Identification and Classification of Members of the Group.
   
  Not Applicable.
   
Item 9. Notice of Dissolution of Group.
   
  Not Applicable.
   
Item 10. Certification.
   
  Not Applicable.

 

8

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 6, 2024

 

  Aisling Capital IV, LP
     
  By: /s/ Andrew Schiff
  Name: Andrew Schiff
  Title: Managing Member
     
  Aisling Capital Partners IV, LP
     
  By: /s/ Andrew Schiff
  Name:  Andrew Schiff
  Title:  Managing Member
     
  Aisling Capital Partners IV LLC
     
  By: /s/ Andrew Schiff
  Name: Andrew Schiff
  Title:  Managing Member
     
  Andrew Schiff
     
  By: /s/ Andrew Schiff
  Name: Andrew Schiff
     
  Steve Elms
     
  By: /s/ Steve Elms
  Name: Steve Elms

 

9

 

 

EXHIBIT LIST

 

Exhibit A  

Joint Filing Agreement, dated as of February 14, 2022, incorporated by reference to the Reporting Persons’ 13G, filed on February 14, 2022.

 

 

10